Unum Therapeutics Receives $65,000,000 Series B Financing

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=9840e418-227c-41f1-aaa8-22f504d586f1
Date
6/11/2015
Company Name
Unum Therapeutics
Mailing Address
One Broadway 4th Floor Cambridge, MA 02142 USA
Company Description
Unum Therapeutics uses proprietary T-cell engineering technology in combination with tumor-targeting antibodies to activate the body’s own immune system to fight cancer.
Website
http://www.unumrx.com
Transaction Type
Venture Equity
Transaction Amount
$65,000,000
Transaction Round
Series B
Proceeds Purposes
The proceeds from the financing will be used to advance the Unum’s novel Antibody-Coupled T-cell Receptor (ACTR) technology platform and support the expansion of the company’s proprietary pipeline of ACTR therapies targeting a broad range of hematological and solid tumor targets.
M&A Terms
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor
Venture Investor